Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

about

Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.

P2860

Q47657705-C0CA682C-2588-4C7F-9E3B-83FD3521F374

P2860

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q38932141

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

@en

type

Item

label

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

@en

prefLabel

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

@en

P1476

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

@en

P2093

Katja Rösch

http://www.w3.org/2001/XMLSchema#string

Markus Scholz

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunoediting from immune surveillance to immune escape

Cancer immunoediting: from immunosurveillance to tumor escape

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Ycasd - a tool for capturing and scaling data from graphical representations

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

P304

1697-1708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1110746

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Hasenclever

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26666299

http://www.w3.org/2001/XMLSchema#string

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

about

P2860

P2860

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698